We invite you to learn more about the exceptional individuals who make up our team:
David M. Geliebter, Executive Chairman, Co-Founder David is a co-founder of Martin Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Remedy Pharmaceuticals, a CNS-focused pharmaceutical company that sold its lead program, CIRARA (now BIIB093), a repositioned orphan drug, to Biogen for an up front of $120 million plus milestones and royalties, and Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award. CLICK HERE TO EMAIL DAVID
Sven M. Jacobson, MBA, CEO, Co-Founder Sven is a co-founder of Martin Pharmaceuticals. Sven has over 20 years of senior management experience. Sven is a Partner at Carrot Capital Healthcare Ventures and co-founder and board member and CEO of Remedy Pharmaceuticals, a CNS-focused pharmaceutical company that sold its lead program, CIRARA (now BIIB093), a repositioned orphan drug, to Biogen for an up front of $120 million plus milestones and royalties. Sven is also a co-founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. Sven co-founded Access Scientific (which was acquired by Endeavour Capital), as well as Cure Therapeutics, and St. Camillus Medical. Sven received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa. CLICK HERE TO EMAIL SVEN
Thomas W. MacAllister, JD, PhD, Vice President of Research and Development, and General Counsel Tom is a pharmaceutical executive with a PhD in molecular biology and over 25 years of experience, including business development, drug discovery, preclinical and clinical development, regulatory strategy, intellectual property acquisition and enforcement, as well as commercialization. Tom has held the positions of CEO Argentum Pharmaceuticals, LLC; Chief Development Officer, Besins Healthcare SA; President & CEO, BHR Pharma LLC, and is currently VP of Research and Development, and General Counsel for Remedy Pharmaceuticals. He is an attorney licensed to practice law in the Commonwealth of Virginia, the District of Columbia and before the United States Patent & Trademark Office. CLICK HERE TO EMAIL TOM
Ann C. Tunstall, PhD, Vice President of Regulatory And Clinical Operations Ann has worked as a regulatory and clinical professional in the healthcare industry for more than 25 years, identifying and implementing effective regulatory and clinical development strategies for novel and repositioned pharmaceuticals and combination products. Ann started her career as a research and development scientist. She has assisted companies in directing and managing clinical trial programs from initial Phase 1 through pivotal Phase 3 trials. Ann has a Ph.D. in Biomedical Engineering from the University of Texas Southwestern Medical Center, an M.S. in Material Science from Duke University, and a B.S. in Biomedical Engineering from Duke University. She is also currently VP of Regulatory and Clinical Operations at Remedy Pharmaceuticals. CLICK HERE TO EMAIL ANN
Roland Gerritsen van der Hoop, MD, PhD, Chief Medical Officer Roland is a pharmaceutical executive with over 30 years of experience in clinical development, regulatory affairs, pharmacovigilance, project management, preclinical and pharmaceutical development, and medical affairs. Roland has held the positions of Chief Medical Officer of Solvay Pharmaceuticals, Chief Scientific Officer of Serologicals and Sr. VP of R&D and Regulatory Affairs of Endo Pharmaceuticals. He has been an independent consultant since 2007 with CMO positions in various other pharmaceutical companies. In these functions he has had numerous interactions with regulatory authorities in EU and US and responsibility for the development of drugs in a variety of therapeutic areas. Roland has an MD and PhD from Utrecht University, the Netherlands. CLICK HERE TO EMAIL ROLAND
Efsevia (Effie) Albanis, MD, Hepatology Advisor Dr. Albanis is a gastroenterologist/hepatologist, with over 10 years of pharmaceutical and biotech experience in medical affairs, clinical development and corporate strategy roles. She has contributed to the development of medications across a myriad of liver diseases including nonalcoholic steatohepatitis (NASH), primary biliary cholangitis, primary sclerosing cholangitis, and hepatitis C and hepatitis B, while at Intercept Pharmaceuticals, Pharmasset/Gilead and Novartis. Effie remains on faculty at the Mt. Sinai Division of Liver Diseases in New York. Prior to joining the pharmaceutical industry, she was a physician-scientist, managing chronic liver disease patients, while also conducting translational research in hepatic fibrosis.